Acute Kidney Injury, Critical Illness
Conditions
Keywords
Acute kidney injury, Biomarker, AKI progression, Poor outcome, Furosemide Stress Test
Brief summary
The aim of this study was to identify and validate novel biomarkers including functional tests for detecting AKI, AKI progression and other poor outcomes.
Detailed description
Cardiac surgery-associated acute kidney injury (CSA-AKI) is the second most common type of AKI after septic AKI and is associated with increased mortality and morbidity. The progression of AKI with multiple organ failure can result in poor outcomes. Several novel biomarkers for earlier detection of AKI, discrimination of etiologies, and prediction of outcomes were developed. However, the availability of these novel biomarkers may be limited by its expense or reimbursement issues in different countries. In present study, we conduct a large cohort to identify and validate novel biomarkers including functional tests for detecting AKI, AKI progression and other poor outcomes.
Interventions
The management for AKI patients were performed by implementing a standard care "bundle" suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline.
Sponsors
Guowei Tu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Inclusion criteria
* Patients undergoing cardiac surgery were prospectively screened, and those who developed AKI within 48 hours post-surgery were included in the study.
Exclusion criteria
* History of End Stage Renal Disease or on Dialysis; * prior kidney transplantation; * patients with a DNR order; * patients without written informed consent; * pregnancy; * moribund patients with expected death within 24 h or whose survival to 28 days was unlikely due to an uncontrollable comorbidity (i.e., end-stage liver or heart disease, untreatable malignancy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AKI progression | 7 days | worsening of KDIGO stage within 1 week (progressing from stage 1 to either stage 2 or stage 3, or from stage 2 to stage 3). Patients diagnosed with progressive or persisting stage 3 AKI (stage 3 AKI for \>3 consecutive days) were classified as having AKI progression. If patients who presented with stage 3 AKI but not requiring RRT subsequently required dialysis or developing persist severe AKI or death within 7 days, this was considered progression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 365 days | Mortality at 30 days, 90 days and 365 days |
| Receipt of renal replacement treatment | 365 days | Patients received renal replacement treatment during hospital stay |
| Major adverse kidney events | 365 days | MAKE was defined as the composite of≥25% loss in estimated glomerular filtration rate (eGFR), dialysis, or death. Estimated GFR was calculated from serum creatinine using the MDRD equation |
| Persistent AKI | 90 days | Persistent AKI is characterized by the continuance of AKI by serum creatinine or urine output criteria (as defined by KDIGO) beyond 48h from AKI onset. |
| Persist severe AKI | 90 days | Persistent severe AKI was defined as follows: Patients with stage 3 AKI at enrollment required a persistence of 72 hours or more to meet the end point. Patients enrolled at stage 2 AKI required a progression to stage 3 within 48 hours and a persistence at stage 3 for 72 consecutive hours to be considered end point positive. Additionally, patients with severe AKI who failed to achieve 72 hours due to death or the initiation of RRT were considered end point positive. |
| Length of stay in the ICU | 90 days | Length of stay in the ICU |
| Length of stay in the hospital | 90 days | Length of stay in the hospital |
| AKI progression to stage 3 | 7 days | worsening of KDIGO stage to stage 3 within 1 week (progressing from stage 1 or stage 2 to stage 3). |
| AKI occurrence at 3 days | 3 days | AKI was defined based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria. |
| AKI occurrence at 7 days | 7 days | AKI was defined based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria. |
Countries
China
Contacts
STUDY_DIRECTORZhe Luo, Professor
Fudan University
Outcome results
None listed